NASP Speciality Pharmacy Podcast

Breaking Down the 2026 Consolidated Appropriations Act and Its Impact on Specialty Pharmacy | NASP Specialty Pharmacy Podcast

In this episode, Sheila Arquette, President & CEO of NASP, speaks with Jonathan L. Swichar, Duane Morris Pharmacy Litigation Group Chair, and Bradley A. Wasser, Duane Morris Pharmacy Litigation Group Partner. They discuss the 2026 Consolidated Appropriations Act and its landmark PBM reform provisions that impact pharmacy network access and transparency. These expert litigators go into detail about what specialty pharmacies should expect as federal agencies enforce the new law and what opportunities and challenges lie ahead for specialty pharmacies.

The New PBM Regulatory Landscape: Talking Enforcement Trends, Contracting Strategies, and Future Opportunities for Specialty Pharmacies | NASP Specialty Pharmacy Podcast

In this episode of the NASP Podcast, Sheila Arquette, President & CEO of NASP, speaks with Linda Clark and Brad Gallagher, Co-Leaders of Barclay Damon’s Health Care Controversies and Pharmacy Teams. They explore the rapidly evolving Pharmacy Benefit Manager (PBM) regulatory landscape and its impact on specialty pharmacies, offering key considerations for contracting and strategies to strengthen audit readiness and compliance. Linda and Brad also share practical guidance to help specialty pharmacies increasingly under pressure to manage their risk and position themselves for long-term success.

From Innovation and Integration to Impact: Advancing Health System Specialty Pharmacy at UC Davis Health | NASP Specialty Pharmacy Podcast

In this episode, Sheila Arquette, President & CEO of NASP, speaks with David G. Mitchell, PharmD, MBA, CSP, FCPhA, Assistant Chief Pharmacy Officer of Specialty Pharmacy & Home Delivery and Ruth Chen, PharmD, MHA, Manager of the Specialty Pharmacy Hub at UC Davis Health in Sacramento. They look at how UC Davis Health has built and scaled one of California’s most integrated health-system specialty pharmacy programs. Dr. Mitchell shares how being embedded within clinics, care teams, and the EHR enables specialty pharmacy to deliver differentiated clinical and operational value while navigating payer, policy, and access challenges in a rapidly evolving landscape. Dr. Chen discusses why a focused rare disease strategy is essential for health-system specialty pharmacies. She walks through the challenges that existed prior to implementing a centralized rare disease hub model and how those challenges shaped the development of a coordinated, pharmacy-led approach that supports patients and providers across complex therapies. Together, this conversation highlights how structure, strategy, and leadership enable innovation, workforce growth, and improved patient care.

The Season to Innovate: Strategic Legal and Regulatory Considerations for Approaching Acquisitions and Vetting AI Vendors | NASP Specialty Pharmacy Podcast

In this episode of the NASP Podcast, Sheila Arquette, President & CEO of NASP, speaks with Simone Colgan Dunlap, National Vice Chair of the Quarles Health and Life Sciences Practice Group, and Amy Cotton Peterson, Partner at Quarles. As more automation solutions become available, its vital specialty pharmacy providers strategically approach acquisition of targets that offer technology and AI assets. This discussion explores effective diligence practices, common pitfalls, and risk mitigation strategies for specialty pharmacies navigating mergers and acquisitions and the rapidly evolving use of artificial intelligence.

Navigating Treatment of Dermatologic Inflammatory Conditions with Specialty Drug Therapies, with Vanderbilt Specialty Pharmacy, Vanderbilt Health | NASP Specialty Pharmacy Podcast

In this episode of the NASP Podcast, Sheila Arquette, President & CEO of NASP, speaks with Matthew G. Bowles, PharmD, MBA, CSP, Pharmacy Clinical Team Lead with Vanderbilt Specialty Pharmacy, Vanderbilt Health, and lead author on the study “Getting to specialty treatment in dermatologic inflammatory conditions: Treatment requirements and patient journey,” published February 2025 in the Journal of Managed Care & Specialty Pharmacy. They discuss the reasons for conducting and results of the study, as well as the impacts the study may have on specialty and managed care pharmacy.